Tenofovir‐based antiviral combination regimens vs placebo or tenofovir alone or non‐tenofovir‐based antiviral regimens
All‐cause infant mortality at longest · HIV‐positive pregnant women co‐infected with hepatitis B virus
It is very uncertain whether tenofovir‐based antiviral combination regimens changes all‐cause infant mortality at longest compared with placebo or tenofovir alone or non‐tenofovir‐based antiviral regimens (very low certainty).
1 finding from 1 review
- Antivirals for prevention of hepatitis B virus mother‐to‐child transmission in human immunodeficiency virus positive… 2023 · Cochrane Headline outcomes onlyRR 2.24 [0.72, 6.96]1 study · 132 participantsVery low